Three Phase 1/2, Open‐label Studies of Cereblon E3 Ligase Modulator (Celmod)‐based Regimens in Newly Diagnosed (Nd) or Relapsed/Refractory (R/R) Non‐hodgkin Lymphoma (Nhl)

Abstract

oral, once-daily ibrutinib 560 mg plus venetoclax in a 5-week rampup to 400 mg. Treatment will continue for up to 24 months, after which venetoclax will be discontinued in all patients and singleagent ibrutinib will continue until progressive disease or unacceptable toxicity. The primary objective is to evaluate the CR rate; secondary objectives include additional efficacy evaluations, safety, and pharmacokinetics. Status: The new arm of the SYMPATICO study conducted in previously untreated patients is currently enrolling at multiple global sites; anticipated completion is in 2022.As of Jan 11, 2021, the study is recruiting only those patients with known TP53 mutations, including those aged 65 and older, for enrollment.EA -previously submitted to regional or national meetings (up to 1000 attendees).